Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Monday that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference, Antibody Engineering and Therapeutics, in San Diego being held from 9 December to 13 December 2018.

This new data will be presented as a poster presentation on 10 December 2018, as well as in a later oral presentation by Dr David Liberg, VP Cancer Research at Cantargia. In addition to the presentation of new data, Cantargia's CEO Dr Göran Forsberg has been invited to give a talk entitled 'IL1RAP as a therapeutic Target' on 11 December 2018. The poster presentation is available at https://www.cantargia.com.

CAN04 is in clinical development for cancer therapy and targets interleukin 1 receptor accessory protein, IL1RAP, positive single agent clinical data was recently presented at ESMO.

According to the company, these new results give further support for an important role of CAN04 also in combination with chemotherapy and provide new insights into the advantages of targeting IL1RAP as a treatment strategy in non-small cell lung cancer, NSCLC.

Cantargia is developing the antibody CAN04 for treatment of cancer. CAN04 is investigated in the CANFOUR phase I/IIa clinical trial and is entering the phase IIa part of that study. This trial is primarily focused on treatment of NSCLC and pancreatic cancer. CAN04 is directed against IL1RAP which is found on tumour cells from a large number of cancer forms including NSCLC. IL1RAP is also found

on inflammatory immune cells contributing to the cancer progression. Positive phase I interim data in heavily pre-treated patients was presented in October 2018 at ESMO, showing good safety, effects on relevant biomarkers and stable disease in 38 % of patients.